Antonello Mai | Ricerc@Sapienza

Publications

Title	Published on	Year
A Xanthine Derivative With Novel Heat Shock Protein 90-Alpha Inhibitory and Senolytic Properties	AGING CELL	2025
HDAC1/2 control mesothelium/ovarian cancer adhesive interactions impacting on Talin-1-α5β1-integrin-mediated actin cytoskeleton and extracellular matrix protein remodeling	JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH	2024
SIRT3 Activation a Promise in Drug Development? New Insights into SIRT3 Biology and Its Implications on the Drug Discovery Process	JOURNAL OF MEDICINAL CHEMISTRY	2024
Mechanisms of mesothelial cell response to viral infections: HDAC1-3 inhibition blocks poly(I:C)-induced type I interferon response and modulates the mesenchymal/inflammatory phenotype	FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY	2024
Specific Inhibitors of Mitochondrial Deacylase Sirtuin 4 Endowed with Cellular Activity	JOURNAL OF MEDICINAL CHEMISTRY	2024
Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer	CANCER CELL INTERNATIONAL	2024
Theileria parasites sequester host eIF5A to escape elimination by host-mediated autophagy	NATURE COMMUNICATIONS	2024
Uracil- and Pyridine-Containing HDAC Inhibitors Displayed Cytotoxicity in Colorectal and Glioblastoma Cancer Stem Cells	CHEMMEDCHEM	2024
Heterocycles-Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years	CHEMMEDCHEM	2024
A host-directed oxadiazole compound potentiates antituberculosis treatment via zinc poisoning in human macrophages and in a mouse model of infection	PLOS BIOLOGY	2024
m6A modification inhibits miRNAs’ intracellular function, favoring their extracellular export for intercellular communication	CELL REPORTS	2024
STRUCTURE-BASED MECHANISM OF RIBOREGULATION OF THE METABOLIC ENZYME SHMT1	MOLECULAR CELL	2024
Pharmacological Activation of SIRT3 Modulates the Response of Cancer Cells to Acidic pH	PHARMACEUTICALS	2024
HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks	CELL DEATH DISCOVERY	2024
Off-target inhibition of human dihydroorotate dehydrogenase (hDHODH) highlights challenges in the development of fat mass and obesity-associated protein (FTO) inhibitors	ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE	2024
Activation and inhibition of sirtuins: From bench to bedside	MEDICINAL RESEARCH REVIEWS	2024
Successes and challenges in the development of BD1-selective BET inhibitors: a patent review	EXPERT OPINION ON THERAPEUTIC PATENTS	2024
Systematic Design of Adenosine Analogs as Inhibitors of a Clostridioides difficile-Specific DNA Adenine Methyltransferase Required for Normal Sporulation and Persistence	JOURNAL OF MEDICINAL CHEMISTRY	2023
METTL3 from Target Validation to the First Small-Molecule Inhibitors: A Medicinal Chemistry Journey	JOURNAL OF MEDICINAL CHEMISTRY	2023
Simultaneous administration of EZH2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells	JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY	2023

1
2
3
4
5
6
7
8
9
10
next >
last »

ERC

PE5_18

KET

Life-science technologies & biotechnologies

Interessi di ricerca

Keywords

drug discovery

Epigenetic drugs

antiviral agents

Anticancer drugs

parasite growth inhibition

Progetti di Ricerca

Italian Centre for Native Mass Spectrometry - INCENTIVE MS
Dual- and multi-targeting epigenetic inhibitors for the treatment of aggressive and/or recurrent cancers.